Henry Schein, Inc. $HSIC Shares Sold by Clarkston Capital Partners LLC

Clarkston Capital Partners LLC trimmed its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.5% during the fourth quarter, Holdings Channel reports. The firm owned 1,477,665 shares of the company’s stock after selling 21,935 shares during the period. Henry Schein comprises about 2.6% of Clarkston Capital Partners LLC’s holdings, making the stock its 11th largest position. Clarkston Capital Partners LLC’s holdings in Henry Schein were worth $111,682,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HSIC. CYBER HORNET ETFs LLC acquired a new stake in shares of Henry Schein during the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein during the 2nd quarter worth approximately $27,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Henry Schein during the 4th quarter worth approximately $30,000. Federated Hermes Inc. bought a new position in Henry Schein in the 4th quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein in the 4th quarter worth approximately $37,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $81.25 on Friday. The stock has a fifty day moving average price of $75.36 and a two-hundred day moving average price of $76.21. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The firm has a market cap of $9.26 billion, a P/E ratio of 24.55, a PEG ratio of 1.55 and a beta of 0.82. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. The firm had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the company posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts forecast that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on HSIC shares. BTIG Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Thursday. Robert W. Baird set a $97.00 price objective on Henry Schein in a report on Wednesday, May 6th. Morgan Stanley reissued an “underweight” rating and issued a $64.00 price objective (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Wall Street Zen lowered Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Finally, Mizuho decreased their price objective on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Henry Schein currently has an average rating of “Hold” and an average target price of $87.85.

Insiders Place Their Bets

In other Henry Schein news, CEO Thomas C. Popeck sold 1,355 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the completion of the transaction, the chief executive officer directly owned 86,182 shares of the company’s stock, valued at approximately $6,273,187.78. This trade represents a 1.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William K. Daniel purchased 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $69.19 per share, with a total value of $691,900.00. Following the completion of the purchase, the director owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.89% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.